Afficher la notice abrégée

Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohort

dc.rights.licenseopenen_US
dc.contributor.authorFOND, G.
dc.contributor.authorSUNHARY DE VERVILLE, P.L.
dc.contributor.authorRICHIERI, R.
dc.contributor.authorETCHECOPAR-ETCHART, D.
dc.contributor.authorKORCHIA, T.
dc.contributor.authorFAUGERE, Melanie
dc.contributor.authorGODIN, O.
dc.contributor.authorSCHURHOFF, F.
dc.contributor.authorBERNA, F.
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorAOUIZERATE, Bruno
dc.contributor.authorCAPDEVIELLE, D.
dc.contributor.authorCHEREAU, I.
dc.contributor.authorCLAUSS-KOBAYASHI, J.
dc.contributor.authorCOULON, N.
dc.contributor.authorDOREY, J.M.
dc.contributor.authorDUBERTRET, C.
dc.contributor.authorDUBREUCQ, J.
dc.contributor.authorMALLET, J.
dc.contributor.authorMISDRAHI, D.
dc.contributor.authorPASSERIEUX, C.
dc.contributor.authorPIGNON, B.
dc.contributor.authorREY, R.
dc.contributor.authorURBACH, M.
dc.contributor.authorLEBOYER, M.
dc.contributor.authorLLORCA, P.M.
dc.contributor.authorLANCON, C.
dc.contributor.authorBOYER, L.
dc.contributor.authorTHE FACE-SZ (FONDAMENTAL ACADEMIC CENTERS OF EXPERTISE FOR SCHIZOPHRENIA), Group
dc.date.accessioned2021-10-19T13:48:53Z
dc.date.available2021-10-19T13:48:53Z
dc.date.issued2021-12-20
dc.identifier.issn0278-5846en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/112808
dc.description.abstractEnBackground: Peripheral inflammation is associated with impaired prognosis in schizophrenia (SZ). Highly sensitive C-reactive protein (hs-CRP) is the most used inflammatory biomarker in daily practice. However, no consensual cut-off has been determined to date to discriminate patients with peripheral inflammation from those without. Aims: To determine if patients with peripheral inflammation between 1 and 3 mg/L had poorer outcomes compared to those with undetectable CRP (<1 mg/L). Method: Consecutive participants of the FACE-SZ cohort with a hs-CRP < 3 mg/L were included in 10 expert academic centers with a national geographical distribution between 2010 and 2018. Potential sources of inflammation, socio-demographics, illness characteristics, current illness severity, functioning and quality of life and were reported following the FACE-SZ standardized protocol. Results: 580 patients were included, of whom 226 (39%) were identified with low-grade inflammation defined by a hs-CRP between 1 and 3 mg/L. Overweight and lack of dental care were identified as potential sources of inflammation. After adjustment for these factors, patients with inflammation had more severe psychotic, depressive and aggressive symptomatology and impaired functioning compared to the patients with undetectable hs-CRP. No association with tobacco smoking or physical activity level has been found. Conclusions: Patients with schizophrenia with hs-CRP level between 1 and 3 mg/L should be considered at risk for inflammation-associated disorders. Lowering weight and increasing dental care may be useful strategies to limit the sources of peripheral inflammation. Hs-CRP > 1 mg/L is a reliable marker to detect peripheral inflammation in patients with schizophrenia.
dc.description.sponsorshipSorbonne Universités à Paris pour l'Enseignement et la Rechercheen_US
dc.description.sponsorshipFondaMental-Cohortesen_US
dc.language.isoENen_US
dc.subject.enInflammation
dc.subject.enPsychiatry
dc.subject.enQuality of life
dc.subject.enSchizophrenia
dc.title.enRedefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohort
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.pnpbp.2021.110335en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed33933539en_US
bordeaux.journalProgress in Neuro-Psychopharmacology and Biological Psychiatryen_US
bordeaux.volume111en_US
bordeaux.hal.laboratoriesNutriNeurO (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINRAEen_US
bordeaux.teamPsychoneuroimmunologie et Nutrition: Approches expérimentales et cliniquesen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDFondation FondaMentalen_US
bordeaux.identifier.funderIDAgence Nationale de la Rechercheen_US
bordeaux.identifier.funderIDInstitut National de la Santé et de la Recherche Médicaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Progress%20in%20Neuro-Psychopharmacology%20and%20Biological%20Psychiatry&amp;rft.date=2021-12-20&amp;rft.volume=111&amp;rft.eissn=0278-5846&amp;rft.issn=0278-5846&amp;rft.au=FOND,%20G.&amp;SUNHARY%20DE%20VERVILLE,%20P.L.&amp;RICHIERI,%20R.&amp;ETCHECOPAR-ETCHART,%20D.&amp;KORCHIA,%20T.&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée